| P2093 | author name string | John Whitesides | |
| | Christian Brandt | |
| | Pavel Klein | |
| | Teresa Gasalla | |
| | Vincent Badalamenti | |
| P2860 | cites work | Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials | Q28248717 |
| | The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men | Q28272717 |
| | Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention | Q30248253 |
| | Anticonvulsant drugs and hematological disease | Q33413868 |
| | A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. | Q34416450 |
| | Assessing abuse liability during drug development: changing standards and expectations. | Q37062910 |
| | Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies | Q37113376 |
| | Hypersensitivity to antiepileptic drugs | Q38228921 |
| | Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment | Q38752407 |
| | Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey | Q38863377 |
| | Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies | Q39428102 |
| | Psychotic disorders induced by antiepileptic drugs in people with epilepsy. | Q39509521 |
| | Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures | Q39707630 |
| | The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males | Q41117944 |
| | Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. | Q42997736 |
| | Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial | Q44773924 |
| | Effect of brivaracetam on cardiac repolarisation--a thorough QT study | Q46501773 |
| | Levetiracetam-associated hyponatremia | Q46515301 |
| | Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users | Q47575581 |
| | Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany. | Q47733662 |
| | Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy | Q47853821 |
| | A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures | Q47926989 |
| | An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam | Q47949546 |
| | Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial | Q48130509 |
| | Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein | Q48383809 |
| | Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. | Q51767935 |
| | Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. | Q51771465 |
| | Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. | Q51910603 |
| | Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. | Q53073031 |
| | Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. | Q54276194 |
| | Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group | Q73122171 |
| | Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial | Q74047711 |
| | Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group | Q74351549 |
| P433 | issue | Pt A | |
| P304 | page(s) | 106864 | |
| P577 | publication date | 2020-01-12 | |
| P1433 | published in | Epilepsy Behavior | Q15746410 |
| P1476 | title | Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis | |
| P478 | volume | 103 | |